Osteosarcoma Market Insights, Sales, Cost and Profit | Forecast to 2027
The Global Osteosarcoma Market has been segmented into type, diagnosis & treatment, end user, and region.
Based on type, the global osteosarcoma market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extraskeletal osteosarcoma. On the basis of diagnosis & treatment, the global osteosarcoma market has been segregated into treatment and diagnosis. The treatment segment is further segmented into chemotherapy, surgery, radiation therapy, and others. The chemotherapy segment includes cisplatin, doxorubicin, epirubicin, and others. The surgery segment includes limb-sparing surgery and amputation.
The diagnosis segment is further segmented into imaging, biopsies, and blood tests. The imaging segment includes computerized tomography (CT), magnetic resonance imaging (MRI), X-Ray, positron emission tomography (PET) and others. The biopsies segment includes needle biopsy and surgical biopsy. The blood tests segment includes alkaline phosphatase profiling, lactate dehydrogenase profiling, and others.
On the basis of end-user, the global osteosarcoma market has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.
Access Report Details @ Market Players https://www.marketresearchfuture.com/reports/osteosarcoma-market-4412 Regional Analysis
Market Research Future (MRFR) recognizes are Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. as the key players in the Global Osteosarcoma Market.
Market Highlights
The Osteosarcoma market in the Americas has been segmented into North America and Latin America. The North American market has been further divided into the US and Canada. The Americas dominate the global Osteosarcoma market, owing to the rising incidence of cancer. According to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in 2018.
Osteosarcoma Market is estimated to be valued at USD 791.08 Million by 2025 and is expected to register a CAGR of 6.09% during the forecast period.
The Global Osteosarcoma Market was valued at USD 522.20 Million in 2018, and the market is estimated to grow to USD 791.08 Million by 2025 and is expected to register a CAGR of 6.09% during the forecast period from 2019 to 2025. In 2018, the Americas accounted for the largest market share of 40.02%, with a market value of USD 6,103.30 million, followed by Europe.
Key Findings of the Study:
Based on type, the intramedullary osteosarcoma segment accounted for the largest market share of 80.30% in 2018, is projected to register a CAGR of 6.25% during the forecast period. On the basis of diagnosis & treatment, the treatment segment accounted for the largest market share of 85.32% in 2018, is projected to register a CAGR of 6.26% during the forecast period.
- The Global Osteosarcoma Market is projected to reach over USD 791.08 Million by 2025 at a 09% CAGR during the review period of 2019 to 2025.
- Americas accounted for the largest market share, with the US being the major contributor to the growth of the market.
- By end-user, hospitals & clinics segment is projected to register the largest market share of 37% during the forecast period. Its largest market share can be attributed to an increase in the number of patients who have cancer, coupled with a rise in a number of hospitals, and quality care, and availability of skilled and qualified professionals.
- Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies.
Browse More Related Reports at:
Medical Marijuana Market Statistics | Global Industry Size, Growth, And Forecast To 2027
CAR T Cell Therapy Market Size, Share, & Trends Analysis | Forecast to 2027
Originally published at http://marketresearchfuturereportr.wordpress.com on June 24, 2021.
